Due to the current situation with COVID-19, we have temporarily paused our in-house user training sessions.
Alternatives such as online training can be arranged with our Global Services & Support Team. Please contact us for further details.
CELLINK AB (publ) (“CELLINK”) has entered into an agreement with the owners of Scienion AG (“Scienion”), a German life science company focusing on precision dispensing technologies, to acquire all shares for a purchase price on cash- and debt-free basis of 80 M euros (the “Acquisition”). 40 M euros will be paid in 2,814,032 newly issued shares of series B in CELLINK (the “Consideration Shares”) and the reminder in cash. CELLINK’s Board of Directors will resolve to issue the Consideration Shares in accordance with the authorization from the Annual General Meeting held on December 18, 2019.
CELLINK also contemplates to explore the conditions for raising additional equity through one directed share issue within the limit of CELLINK’s existing authorization to issue shares from the Extraordinary General Meeting held on July 16, 2020.